Zealand Pharma A/S (FRA:22Z)

Zealand Pharma Statistics

Total Valuation

Zealand Pharma has a market cap or net worth of EUR 3.71 billion. The enterprise value is 1.75 billion.

Market Cap	3.71B
Enterprise Value	1.75B

Important Dates

The last earnings date was Thursday, February 19, 2026.

Earnings Date	Feb 19, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	70.61M
Shares Outstanding	n/a
Shares Change (YoY)	+7.70%
Shares Change (QoQ)	+0.08%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	55.91M

Valuation Ratios

The trailing PE ratio is 4.30 and the forward PE ratio is 33.73.

PE Ratio	4.30
Forward PE	33.73
PS Ratio	3.01
PB Ratio	1.87
P/TBV Ratio	1.88
P/FCF Ratio	4.27
P/OCF Ratio	4.25
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 1.88, with an EV/FCF ratio of 2.01.

EV / Earnings	2.02
EV / Sales	1.41
EV / EBITDA	1.88
EV / EBIT	1.88
EV / FCF	2.01

Financial Position

The company has a current ratio of 23.57, with a Debt / Equity ratio of 0.03.

Current Ratio	23.57
Quick Ratio	23.20
Debt / Equity	0.03
Debt / EBITDA	0.06
Debt / FCF	0.06
Interest Coverage	238.04

Financial Efficiency

Return on equity (ROE) is 55.06% and return on invested capital (ROIC) is 1,401.57%.

Return on Equity (ROE)	55.06%
Return on Assets (ROA)	33.97%
Return on Invested Capital (ROIC)	1,401.57%
Return on Capital Employed (ROCE)	45.26%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	2.51M
Profits Per Employee	1.76M
Employee Count	440
Asset Turnover	0.72
Inventory Turnover	n/a

Taxes

In the past 12 months, Zealand Pharma has paid 73.12 million in taxes.

Income Tax	73.12M
Effective Tax Rate	7.80%

Stock Price Statistics

The stock price has decreased by -51.68% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-51.68%
50-Day Moving Average	58.34
200-Day Moving Average	58.00
Relative Strength Index (RSI)	36.41
Average Volume (20 Days)	30

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Zealand Pharma had revenue of EUR 1.23 billion and earned 864.30 million in profits. Earnings per share was 12.08.

Revenue	1.23B
Gross Profit	1.23B
Operating Income	926.18M
Pretax Income	937.42M
Net Income	864.30M
EBITDA	927.51M
EBIT	926.18M
Earnings Per Share (EPS)	12.08

Balance Sheet

The company has 2.02 billion in cash and 54.33 million in debt, with a net cash position of 1.97 billion.

Cash & Cash Equivalents	2.02B
Total Debt	54.33M
Net Cash	1.97B
Net Cash Per Share	n/a
Equity (Book Value)	1.99B
Book Value Per Share	28.12
Working Capital	2.01B

Cash Flow

In the last 12 months, operating cash flow was 874.60 million and capital expenditures -4.47 million, giving a free cash flow of 870.14 million.

Operating Cash Flow	874.60M
Capital Expenditures	-4.47M
Free Cash Flow	870.14M
FCF Per Share	n/a

Margins

Gross margin is 99.99%, with operating and profit margins of 75.06% and 70.05%.

Gross Margin	99.99%
Operating Margin	75.06%
Pretax Margin	75.98%
Profit Margin	70.05%
EBITDA Margin	75.17%
EBIT Margin	75.06%
FCF Margin	70.52%

Dividends & Yields

Zealand Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.70%
Shareholder Yield	-7.70%
Earnings Yield	23.28%
FCF Yield	23.43%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Zealand Pharma has an Altman Z-Score of 21.93 and a Piotroski F-Score of 7.

Altman Z-Score	21.93
Piotroski F-Score	7